[go: up one dir, main page]

NO20064309L - Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer - Google Patents

Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer

Info

Publication number
NO20064309L
NO20064309L NO20064309A NO20064309A NO20064309L NO 20064309 L NO20064309 L NO 20064309L NO 20064309 A NO20064309 A NO 20064309A NO 20064309 A NO20064309 A NO 20064309A NO 20064309 L NO20064309 L NO 20064309L
Authority
NO
Norway
Prior art keywords
group
4alkyl
alkyl
cyano
halogen
Prior art date
Application number
NO20064309A
Other languages
English (en)
Inventor
Romano Di Fabio
Luca Arista
Luca Tarsi
Silvia Terreni
Anna Maria Capelli
Gabriella Gentile
Fabrizio Micheli
Dieter Hamprecht
Giorgio Bonanomi
Federica Damiani
Giovanna Tedesco
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403990A external-priority patent/GB0403990D0/en
Priority claimed from GB0404083A external-priority patent/GB0404083D0/en
Priority claimed from GB0417120A external-priority patent/GB0417120D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20064309L publication Critical patent/NO20064309L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det beskrives nye forbindelser med formel (I) eller et farmasøytisk akseptabelt salt derav der G er valgt fra gruppen bestående av fenyl, pyridyl, benzotiazolyi, indazolyl; p er et helt tall fra 0 til 5; R1 uavhengig er valgt fra en gruppe bestående av halogen, hydroksy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoksy, haloC1-4alkoksy, C1-4alkanoyl; eller tilsvarer en gruppe R5; R2 er hydrogen eller C1-4alkyl; R3 er C1-4alkyl; R4 er hydrogen, eller en fenyl gruppe, en heterocyklyl gruppe, en 5- eller 6-leddet, heteroaromatisk gruppe, eller en 8- til 11-leddet, bicyklisk gruppe, der en hver av disse grupper eventuelt er substituert med 1, 2, 3 eller 4 substituenter valgt fra gruppen bestående av halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoksy, C1-4alkanoyl; R5 er en del valgt fra gruppen bestående av: isoksazolyl, CH2-N-pyrrolyl, 1,1-dioksido-2-isotiazolidinyl, tienyl, tiazolyl, pyridyl, 2-pyrrolidinonyl, og en slik gruppe eventuelt er substituert med en eller to substituenter valgt blant: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoksy, C1-4alkanoyl; og, når R1 er klor og p er 1, en slik R1 ikke er tilstede i orto posisjon med henblikk på den forbindende binding til resten av molekylet; og når R1 tilsvarer R5, p er 1. Videre beskrives fremgangsmåter for deres fremstilling, mellomprodukter som anvendes i fremgangsmåtene samt farmasøytiske preparater inneholdende forbindelser og preparatenes anvendelse i terapi som modulatorer av dopamin D3 reseptorer, for eksempel for å behandle medikamentavhengighet eller som antipsykotiske midler.
NO20064309A 2004-02-23 2006-09-22 Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer NO20064309L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0403990A GB0403990D0 (en) 2004-02-23 2004-02-23 Compounds
GB0404083A GB0404083D0 (en) 2004-02-24 2004-02-24 Compounds
GB0417120A GB0417120D0 (en) 2004-07-30 2004-07-30 Compounds
PCT/EP2005/001940 WO2005080382A1 (en) 2004-02-23 2005-02-21 Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors

Publications (1)

Publication Number Publication Date
NO20064309L true NO20064309L (no) 2006-11-23

Family

ID=34890800

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064309A NO20064309L (no) 2004-02-23 2006-09-22 Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer

Country Status (25)

Country Link
US (3) US7855298B2 (no)
EP (3) EP2060570B1 (no)
JP (1) JP4960217B2 (no)
KR (1) KR101143718B1 (no)
CN (1) CN1946714B (no)
AR (1) AR047890A1 (no)
AT (3) ATE451364T1 (no)
AU (2) AU2005215918C1 (no)
BR (1) BRPI0507945A (no)
CA (1) CA2557115C (no)
CY (3) CY1109854T1 (no)
DE (1) DE602005018190D1 (no)
DK (3) DK1745040T3 (no)
ES (2) ES2380990T3 (no)
HR (3) HRP20100114T1 (no)
IL (1) IL177184A0 (no)
MA (1) MA28438B1 (no)
NO (1) NO20064309L (no)
PE (1) PE20051173A1 (no)
PL (3) PL1745040T3 (no)
PT (3) PT2070922E (no)
RU (1) RU2434011C2 (no)
SI (3) SI1745040T1 (no)
TW (1) TW200538113A (no)
WO (1) WO2005080382A1 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946714B (zh) * 2004-02-23 2011-06-15 葛兰素集团有限公司 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
US7807698B2 (en) 2005-06-14 2010-10-05 Glaxo Group Limited Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
WO2007006117A1 (en) * 2005-07-13 2007-01-18 Nicogen Inc. Novel cyp2a6 inhibitors
KR101733180B1 (ko) * 2005-07-27 2017-05-08 뉴로반스, 인크. 신규 1-아릴-3-아자바이사이클로［3.1.0］헥산：제조 방법 및 신경 정신 질환 치료를 위한 용도
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
ATE487715T1 (de) 2005-08-22 2010-11-15 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3- rezeptoren
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
KR20080109063A (ko) 2006-04-03 2008-12-16 글락소 그룹 리미티드 도파민 ｄ3 수용체 조절제로서의 아자비시클로[3.1.0]헥실 유도체
GB0607899D0 (en) * 2006-04-03 2006-05-31 Glaxo Group Ltd Process for preparing heterocyclic derivatives
GB0703387D0 (en) * 2007-02-21 2007-03-28 Glaxo Group Ltd Novel compounds
WO2007113258A1 (en) * 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
JP5189076B2 (ja) * 2006-04-03 2013-04-24 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキシル誘導体
GB0608452D0 (en) * 2006-04-27 2006-06-07 Glaxo Group Ltd Novel compounds
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
EP2167083B1 (en) * 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0719235D0 (en) 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
GB0719234D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
CN102816106A (zh) 2008-06-24 2012-12-12 默沙东公司 用于制备基本上立体异构纯的稠合二环脯氨酸化合物的生物催化方法
KR20130105914A (ko) 2008-09-22 2013-09-26 카이맨 케미칼 컴파니 인코포레이티드 Ｈ-ｐｇｄｓ 억제제로서 다중헤테로아릴 화합물 및 프로스타글란딘 ｄ2 매개된 질병의 치료를 위한 그의 용도
RU2012102094A (ru) * 2009-06-26 2013-08-10 Панацеа Биотек Лтд. Новые азабициклогексаны
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20160279098A1 (en) * 2013-11-11 2016-09-29 Euthymics Bioscience, Inc. Novel methods
ES2821896T3 (es) * 2015-08-05 2021-04-28 Indivior Uk Ltd Antagonistas del receptor de dopamina D3 que tienen una unidad estructural biciclo
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
CA3187566A1 (en) 2020-06-22 2021-12-30 Corcept Therapeutics Incorporated Quaternary indazole glucocorticoid receptor antagonists
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
CA3243549A1 (en) 2021-12-21 2023-06-29 Corcept Therapeutics Incorporated INDAZOLE PIPERAZINE-BASED GLUCOCORTICOID RECEPTOR ANTAGONISTS
MX2024007586A (es) 2021-12-21 2024-09-04 Corcept Therapeutics Inc Antagonistas indazólicos bicíclicos del receptor de glucocorticoides.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022228A1 (es) * 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
BR0115328A (pt) * 2000-11-14 2004-04-06 Smithkline Beecham Plc Derivados de tetraidro benzazepina úteis como moduladores dos receptores d3 de dopamina (agentes anti-psicóticos
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
BR0213464A (pt) * 2001-10-22 2004-11-09 Pfizer Prod Inc Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
CA2494987C (en) * 2002-08-09 2012-04-17 Astrazeneca Ab Isoxazoles and their use as modulators of metabotropic glutamate receptor-5
CN1946714B (zh) * 2004-02-23 2011-06-15 葛兰素集团有限公司 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
US7807698B2 (en) * 2005-06-14 2010-10-05 Glaxo Group Limited Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
ATE487715T1 (de) * 2005-08-22 2010-11-15 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3- rezeptoren
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
KR20080109063A (ko) * 2006-04-03 2008-12-16 글락소 그룹 리미티드 도파민 ｄ3 수용체 조절제로서의 아자비시클로[3.1.0]헥실 유도체
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
SI1745040T1 (sl) 2010-04-30
DE602005018190D1 (de) 2010-01-21
EP1745040B1 (en) 2009-12-09
SI2070922T1 (sl) 2011-12-30
HRP20100114T1 (hr) 2010-04-30
EP2060570A3 (en) 2009-06-03
US20070142438A1 (en) 2007-06-21
CA2557115A1 (en) 2005-09-01
US20100152195A1 (en) 2010-06-17
IL177184A0 (en) 2006-12-10
AU2005215918A1 (en) 2005-09-01
AU2005215918B2 (en) 2009-06-11
JP4960217B2 (ja) 2012-06-27
MA28438B1 (fr) 2007-02-01
ES2337590T3 (es) 2010-04-27
EP1745040A1 (en) 2007-01-24
PE20051173A1 (es) 2006-02-14
CA2557115C (en) 2012-10-02
CY1113029T1 (el) 2016-04-13
HK1103016A1 (en) 2007-12-14
ES2380990T3 (es) 2012-05-22
WO2005080382A1 (en) 2005-09-01
HRP20110781T1 (hr) 2011-11-30
CY1109854T1 (el) 2014-09-10
ATE451364T1 (de) 2009-12-15
TW200538113A (en) 2005-12-01
ATE542816T1 (de) 2012-02-15
CY1112011T1 (el) 2015-11-04
BRPI0507945A (pt) 2007-07-24
CN1946714B (zh) 2011-06-15
US8283474B2 (en) 2012-10-09
EP2060570B1 (en) 2012-01-25
US7855298B2 (en) 2010-12-21
PT2060570E (pt) 2012-05-07
PL2070922T3 (pl) 2012-01-31
RU2434011C2 (ru) 2011-11-20
JP2007523208A (ja) 2007-08-16
SI2060570T1 (sl) 2012-05-31
US20100160336A1 (en) 2010-06-24
ATE520686T1 (de) 2011-09-15
PT2070922E (pt) 2011-11-24
EP2070922B1 (en) 2011-08-17
AU2005215918C1 (en) 2010-01-21
EP2070922A1 (en) 2009-06-17
AU2009212887A1 (en) 2009-09-24
PL1745040T3 (pl) 2010-05-31
DK2060570T3 (da) 2012-04-30
HRP20120281T1 (hr) 2012-04-30
DK2070922T3 (da) 2011-11-28
RU2006133909A (ru) 2008-03-27
PL2060570T3 (pl) 2012-06-29
KR101143718B1 (ko) 2012-07-05
EP1745040B9 (en) 2010-06-02
KR20060127991A (ko) 2006-12-13
CN1946714A (zh) 2007-04-11
PT1745040E (pt) 2010-03-08
AR047890A1 (es) 2006-03-01
EP2060570A2 (en) 2009-05-20
US8263782B2 (en) 2012-09-11
DK1745040T3 (da) 2010-04-12

Similar Documents

Publication Publication Date Title
NO20064309L (no) Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer
DE602006018152D1 (de) Triazolderivate als modulatoren von dopamin-d3-rezeptoren
CO6251248A2 (es) Compuestos de tiazolopiridina como moduladores de sirtuina
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
AR060237A1 (es) Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende.
TW200604186A (en) Compounds
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
NO20092224L (no) Quiniklidinderivater av (hetero)arylcykloheptankarboksylsyre som muskarinreseptorantagonister
MY152805A (en) Benzazepine derivatives useful as vasopressin antagonists
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR067412A1 (es) Moduladores de propiedades farmaceuticas de productos terapeuticos
ATE493404T1 (de) Azabicyclo-(3,1,0)-hexan-derivate als modulatoren von dopamin-d3-rezeptoren
AR077367A1 (es) 2- carboxamida -cicloamino-ureas sustituidas
MY153042A (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
CY1112679T1 (el) Κινολινες και θεραπευτικη χρηση αυτων
NO20063355L (no) Nye trisykliske spiroderivater som modulatorer for kemokinreseptoraktivitet
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
DE602006011725D1 (de) 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3-rezeptors
DE602006017543D1 (de) Neue verbindungen
MX2012008147A (es) Derivados de pirrazolopiridina.
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
IN2012DN02871A (no)
ATE539053T1 (de) Azabicyclo ä3. 1. 0ü-hexylderivate als modulatoren von dopamin-d3-rezeptoren
ATE452636T1 (de) 3-azabicycloä4.1.0üheptan-derivate zur behandlung von depressionen

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application